Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: an observational prospective study

  • Mohamed Zeriouh1,
  • Anton Sabashnikov1Email author,
  • Yeong-Hoon Choi1, 3,
  • Javid Fatullayev1,
  • Hannes Reuter2,
  • Aron-Frederik Popov4,
  • Georg Langebartels1,
  • Lucas Kimmig2,
  • Parwis B Rahmanian1,
  • Thorsten Wittwer1, 3,
  • Klaus Neef3,
  • Jens Wippermann1 and
  • Thorsten Wahlers1, 3
Contributed equally
Journal of Cardiothoracic Surgery20149:83

https://doi.org/10.1186/1749-8090-9-83

Received: 16 January 2014

Accepted: 24 April 2014

Published: 12 May 2014

Abstract

Objective

The aim of this prospective observational study was to evaluate the efficiency of a new escalating treatment strategy with vernakalant, flecainide and electrical cardioversion (EC) in patients with new onset atrial fibrillation (AF) after cardiac surgery.

Material and methods

24 patients with new onset AF after aortic valve surgery, coronary artery bypass surgery or combined procedures were evaluated in this study. Additional including criteria were age between 18 and 80, duration of AF less than four days, body weight less than 100 kg and no previous treatment with class I or III antiarrhythmic drugs. Exclusion criteria were poor left ventricular ejection fraction (LVEF < 40%) and history of myocardial infarction within 30 days. The patients were divided into converters and non-converters according to their response to combination treatment with vernakalant and flecainide, and the groups were compared.

Results

The mean age of the population was 69.6 ± 6.3 years and 26.1% of patients were female. There were no statistically significant differences between the two groups in terms of height, weight, gender distribution, comorbidities, preoperative medication, left ventricular function and left atrium diameter. Interventricular septum (IVS) in the non-converted group was significantly thicker compared to the converted group: 14.0 ± 1.00 vs. 10.40 ± 2.59 mm (p = 0.036). While 14 patients (60.9%) were successfully converted into stable sinus rhythm by pharmacological treatment with vernakalant and flecainide, 9 patients (39.1%, non-converted group) remained in AF. However, seven of them could be converted after additional EC.

Conclusion

The combination of vernakalant and flecainide improves the conversion rate into a stable sinus rhythm in postcardiotomy patients with new onset AF compared to single drug therapy. Furthermore it might be an excellent precondition for successful EC in patients who are not converted after using both antiarrhtythmic drugs. Furthermore, left ventricular hypertrophy might be a potential negative predictor of successful pharmacological cardioversion.

Keywords

VernakalantFlecainideRecent onset atrial fibrillation post cardiac surgeryElectrical cardioversionAntiarrhythmic drugs

Background

Postoperative atrial fibrillation (AF) is the most common complication after cardiac surgery, which occurs in up to 74% of patients who underwent on-pump and off-pump procedures[1, 2]. Furthermore, it may contribute to longer hospital stays which can be associated with deterioration in heart failure, prolonged inotropic support, use of intraaortic balloon pump, and increased risk for cerebrovascular accidents[3, 4]. After more than a century of research, the etiology and pathophysiology of this arrhythmia is still not completely understood[2, 5]. In terms of treatment, there are several drugs, such as digitalis, Beta-blockers, calcium channel-blockers, and pharmacological or electrical cardioversion (EC), which were shown as efficient treatment strategies of AF in patients undergoing cardiac surgery[6]. The choice of treatment in each individual case depends on a number of factors, such as age, comorbidities and clinical status of patients with AF. Also, duration and etiology of AF play a major role in the treatment choice[7].

If not approached within a short period of time, a delayed cardioversion may aggravate AF-associated symptoms and promote structural changes of the atria[8]. Therefore, it is of particular interest to achieve early cardioversion in patients with AF, especially when they suffer from distressing symptoms or seriously compromised cardiac function[1, 3, 911].

Vernakalant is an antiarrhythmic agent, which is used for rapid cardioversion of recent onset atrial fibrillation. It blocks early-activating K+ atrial channels and frequency-dependent atrial Na+ channels, prolongs atrial refractory periods and decreases atrial conduction without promoting ventricular arrhythmia[12]. Flecainide is a class Ic antiarrhythmic agent, which can be used for the prevention of ventricular and supraventricular arrhythmias[13]. Electrical cardioversion delivers a direct current synchronization with the R wave. It is usually done using external, transcutaneous electrode patches or internal cardiac electrodes[14]. All these treatment strategies have been shown as valuable options in case of postcardiotomy AF[1214], however so far there has been no evidence regarding efficacy of stepwise escalating therapy using vernacalant, flecainide and EC after cardiac surgery.

In this study, we created a new cardioversion protocol and assessed its cardioversion efficacy in postoperative patients with recent new onset AF.

Methods

Patients

Between December 2011 and September 2012, 24 patients with new onset AF who underwent isolated or combined aortic valve replacement and/or coronary artery bypass surgery performed at our institution were evaluated in this observational prospective study. Inclusion criteria were: age between 18 and 80, duration of new onset AF less than 4 days, body weight less than 100 kg and no previous treatment with class I or III antiarrhythmic drugs. Preoperative exclusion criteria were: poor left ventricular ejection fraction (LVEF < 40%), NYHA class III-IV, history of myocardial infarction within 30 days before surgery, long QT syndrome (uncorrected QT interval > 440 ms), sick sinus node syndrome, higher degree atrio-ventricular block (II°, III°) as well as bradyarrhythmia absoluta. Re-do cardiac surgery patients were also excluded from this observation.

Ethical clearance for this observational prospective study was given by the institutional ethics committee of Cologne University. Therefore, according to the Ethics Committee a signed informed consent was not mandatory as both antiarrhythmic drugs used were approved in the ESC Guidelines and the risks are similar to the current standard therapy[15].

Study protocol

Patients with new onset AF after a cardiac surgical procedure underwent treatment according to the protocol shown in Figure 1. In all patients who were not effectively anticoagulated for more than 48 hours after new onset AF, an elective pre-interventional trans-esophageal echocardiography was performed in order to exclude intracardiac thrombus formations before pharmacological and/or electrical cardioversion were commenced. Before the first vernakalant administration, electrolyte levels (magnesium, potassium) were checked and optimized, if indicated.
Figure 1

Flowchart of studyprotcol which begins with the admission to ICU with bloodpressure-, oxygen saturation measurement and blood sample collection and ends with EC.

Electric cardioversion under sedation with weight adjusted etomidate was only performed in case of persistent AF after sequential pharmacological treatment with both vernakalant and flecainide. A successful cardioversion was defined as a conversion into a stable sinus rhythm within the time periods described in Figure 1.

Furthermore, according to the study protocol, all patients were divided in two groups: patients who successfully converted into a stable SR (converted group) and patients who were not converted into a SR (non-converted group) after single treatment with vernakalant or combination vernakalant/flecainide before EC. Both groups were compared regarding patients baseline preoperative, intraoperative and postoperative characteristics, past medical history, laboratory and echocardiographic parameters before treatment with the view to elaborating possible predictors of non-responders to pharmacological treatment.

Statistical analysis

All data were analyzed using Statistical Package for Social Sciences, version 21.0 (SPSS Inc., Chicago, Illinois) and are expressed as the mean ± standard deviation (SD) in cases of normal distributed or median (interquartile range) in cases of non-normal distributed continuous variables. Variables were tested for normal distribution using the one sample Kolmogorov-Smirnov test. The Student t test and the Mann–Whitney U test were applied for comparison of continuous variables in case of normal or non-normal distribution, respectively. Chi-square and Fisher exact test were used for comparison of dichotomous variables. A p-value < 0.05 was considered to indicate statistical significance.

Results

Tables 1,2 and3 represent basic demographic data, patient comorbidities, medical history, echocardiographic parameters and general clinical characteristics of all patients included in this study.
Table 1

Laboratory parameters

Preoperative laboratory parameters

All

Converted n = 14

Non-converted n = 9

p-value

aPTT (sec)

26 (24;28)

26.5 (24.8;28)

24 (24;34)

0.557

Creatinin (mg/dl)

0.91 (0.79;1.14)

0.905 (0.81;1.11)

1.0 (0.81;1.24)

0.557

CRP (mg/l)

3.2 (3;15.4)

3.2 (3;20.8)

3 (3;11.8) 0.877

0.877

CK (U/l)

75.5 (63.5;149.8)

77 (64.5;138)

76 (61;192.5)

0.781

CK-MB (U/l)

15 (15;21)

15 (11.5;17)

18 (12;25)

0.516

GOT (U/l)

26 (23;28.8)

25.5 (19.8;28.5)

27 (23;31)

0.557

GPT(U/l)

21 (15;24)

20 (14.5;28)

21 (16;23.5)

0.744

Hemoglobin (g/dl)

13.3 ± 2.1

13.3 ± 2.4

13.5 ± 1.9

0.831

Quick (%)

90.1 ± 20.5

89.6 ± 17.1

89.7 ± 26.8

0.992

Platelets (x1E9/l)

211.5 ± 70.6

207.9 ± 76.2

216.8 ± 69.5

0.780

Troponin-T (ug/l)

0.42 ± 0.82

0.26 ± 0.39

0.77 ± 1.33

0.492

Uric acid (mg/dl)

46.8 ± 17.1

49.6 ± 19.7

44 ± 12.6

0.460

WCC (x1E9/l)

8.5 ± 1.8

8.9 ± 1.6

8.2 ± 2

0.370

Postoperative but before cardioversion

    

Ca (mmol/l)

2.1 ± 0.15

2.11 ± 0.16

2.1 ± 0.15

0.729

Creatinin (mg/dl)

1.57 ± 0.97

1.35 ± 0.77

2.0 ± 1.15

0.113

CRP (mg/l)

126 ± 91.5

128.9 ± 99.5

122.7 ± 89.2

0.880

Erythrocytes (x1E12/l)

3.46 ± 0.34

3.5 ± 3.9

3.4 ± 0.2

0.291

Hematocrit (%)

31.21 ± 3.22

31.6 ± 3.5

31.1 ± 2.8

0.742

Hemoglobin (g/dl)

10.15 ± 1.0

10.3 ± 1.1

10.1 ± 0.88

0.741

HbA1c (%)

5.83 ± 0.87

5.8 ± 0.95

5.9 ± 0.77

0.924

MCH (pg)

29.4 ± 1.53

29.0 ± 1.4

29.9 ± 1.7

0.178

MCV (fl)

90.0 ± 4.04

88.9 ± 3.3

91.6 ± 4.9

0.127

Mg (mmol/l)

1.05 ± 0.28

1.11 ± 0.34

0.96 ± 0.19

0.267

NtproBNP (ng/l)

1576 (833;3573)

1463 (721;2772)

3102 (1087;11838)

0.185

Potassium (mmol/l)

4.70 ± 0.64

4.5 ± 0.49

4.9 ± 0.83

0.153

PTC (ug/l)

0.5 (0.2;0.88)

0.6 (0.2;0.75)

0.4 (0.23 ± 3.5)

0.645

Platelets (x1E9/l)

219.3 ± 82.2

214.1 ± 93.5

232.6 ± 68.7

0.616

Sodium (mmol/l)

140.4 ± 3.7

140.1 ± 3.4

141.2 ± 4.3

0.511

TSH (mU/l)

2.37 ± 3.97

2.9 ± 4.9

1.7 ± 1.9

0.501

WCC (x1E9/l)

12.25 ± 5.5

12.12 ± 4.9

12.9 ± 6.7

0.761

aPTT: activated partial thromboplastin time, CK: creatine kinase, CRP: c-reactive protein, GOT:glutamic oxaloacetic transaminase, GPT: glutamate pyruvate transaminase, HbA1c: Glycated haemoglobin, MCH: mean corpuscular haemoglobin, MCV: mean corpuscular volume, NtproBNP: N-terminal prohormone of brain natriuretic peptide, PTC: procalcitonin, TSH:thyroid-stimulating hormone, WCC: white cell counts.

Table 2

Baseline characteristics, past medical history and preoperative medication

 

All

Converted n = 14

Non-converted n = 9

p-value

Age

69.63 ± 6.34

68.21 ± 7.21

71.22 ± 4.58

0.279

CVA (%)

13

21.4

0

0.253

COPD (%)

13

14.3

11.1

1.000

Diabetis mellitus (%)

17.4

14.3

22.2

1.000

Female (%)

26.1

21.4

33.3

0.643

Height (cm)

172.71 ± 8.33

172.64 ± 8.28

172 ± 9

0.862

Hyperlipidemia (%)

43.5

42.9

44.4

1.000

Hypertension (%)

78.3

78.6

77.8

1.000

PAD (%)

8.7

7.1

11.1

1.000

Renal insufficiency or creatinin >1.1 (%)

8.7

7.1

11.1

1.000

Smoker (%)

21.7

28.6

11.1

0.611

Weight (kg)

80.56 ± 13.17

81.24 ± 14.26

79.33 ± 12.87

0.748

ACE-inhibitors(%)

36.4

23.1

55.6

0.187

Aspirin (%)

86.4

84.6

88.9

1.000

Beta-blockers (%)

72.7

69.2

77.8

1.000

Ca-antagonist (%)

36.4

30.8

44.4

0.662

Clopidogrel (%)

4.5

7.7

0

1.000

Cortison (%)

4.5

7.7

0

1.000

Diuretics (%)

31.8

38.5

22.2

0.648

Statin (%)

63.6

69.2

55.6

1.000

COPD: chronic obstructive pulmonary disease,CVA: cerebrovascular accident, PAD: peripheral arterial disease.

Table 3

Intraoperative, postoperative and echocardiography data

 

All

Converted n = 14

Non-converted n = 9

p-value

Cardioplegia type

   

0.444

Buckberg (%)

40

46.3

28.6

 

Calafiore (%)

60

53.8

71.4

 

CPB time (min)

109.86 ± 51.3

122.15 ± 59.54

94.13 ± 33.01

0.240

Operation duration (min)

233.52 ± 88.41

242.92 ± 114.4

223.33 ± 38.58

0.628

Operation urgency

   

0.441

Emergent (%)

4.3

7.1

0.0

 

Urgent (%)

13

7.1

22.2

 

Elective (%)

82.6

85.7

77.8

 

Reperfusion time (min)

36.41 ± 22.08

38 ± 26.32

36.63 ± 14.11

0.894

Total ischemic time (min)

64.05 ± 33.66

71.46 ± 38.27

52.5 ± 25.13

0.230

Hospital stay (days)

16.29 ± 5.72

16.4 ± 6.29

15.67 ± 5.61

0.818

Intensive care unit stay (days)

4 (2.75;6.25)

4 (3;6)

4 (2;19.5)

0.972

IABP

5

0

14.3

0.350

Ventilation duration (in hours)

17.45 ± 8.44

18.94 ± 10.31

49.67 ± 13.32

0.256

Ejection fraction (%)

55.82 ± 9.68

58 ± 8.43

42.33 ± 5.51

0.779

Left atrium (mm)

43.22 ± 7.5

41 ± 6.56

42.33 ± 5.51

0.779

Mitral insufficiency (%)

20

25

0

1.000

Interventricular septum (mm)

11.5 ± 2.59

10.43 ± 2.3

14 ± 1

0.036

CPB: Cardiopulmonary bypass, IABP: Intra-aortic balloon pump.

The mean age of the population was 69.6 ± 6.3 years and 26.1% of patients were female. 14 patients (60.9%) were successfully converted into a stable sinus rhythm after treatment with vernakalant or combination vernakalant/flecainide. A stable sinus rhythm could be restored in 12 patients (52.2%) after isolated treatment with vernakalant, and in 2 further patients (cumulative 60.9%) after additional dose of flecainide. One patient refused to proceed with pharmacological treatment after the first dose of vernakalant. Another patient refused EC after not successful drug combination treatment (Figure 2). In total, we were able to achieve a stable SR in 21 patients (95.5%) after treatment with both antiarrhythmic drugs and EC.
Figure 2

Flowchart of studydesign and success of antiarrhythmic drugs and EC.

Comparing converters vs. non-converters after pharmacological treatment, there were no statistically significant differences in terms of height, weight, gender distribution, comorbidities, preoperative medication, left ventricular function and left atrium diameter between both groups (Tables 1,2 and3). However, we found that the interventricular septum (IVS) in the non-converted group was significantly thicker compared to the converted group: 14.0 ± 1.00 vs. 10.40 ± 2.59 mm (p = 0.036).

Discussion

In this study, we investigated for the first time, a graduated scheme therapy of postcardiotomy AF with vernakalant, flecainide and EC. Notably, previous research on AF after cardiac surgery was limited to the use of single therapy with either vernakalant, other antiarrhythmic drugs or/and EC. By comparing converted vs. non-converted patients before EC we found significant difference in the thickness of IVS, which therefore might be a potential negative predictor of successful pharmacological cardioversion.

The negative effect of long term AF has been extensively studied in the previous research[2, 16, 17]. The incidence of AF in postcardiotomy patients may also depend on the type of surgery. It occurs in 32 - 44% after coronary artery bypass grafting (CABG), 35% after OPCAB, 42% after mitral valve, 49%-74% after aortic valve surgery, and 62% of CABG combined with valve surgery[2, 18]. AF after cardiac surgery is associated with longer ICU stay and complications, such as low output syndrome, renal failure and stroke[1922]. There is also a substantial amount of research, mentioned in the updated Guidelines, associating AF with an increased risk of heart failure and high mortality[23]. These facts enhance the importance of rapid cardioversion in order to avoid further adverse events.

Flecainide is a class Ic antiarrhythmic agent which plays an important role in rhythm control in patients with AF and can be administered both orally and intravenously. Vernakalant is a new alternative intravenous atrial selective antiarrhythmic drug developed for rapid conversion of AF into sinus rhythm[24]. This is a sodium- and potassium-channel blocking agent, which effects all phases (0 – IV) of the atrial action potential (AP) and terminates AF by increasing the atrial effective refractory period (AERP) by blocking the potassium (IKur, IKACh, IKr and Ito) and sodium currents (INa) in a concentration-, rate- and voltage-dependent manner[25].

The effect of vernakalant on the treatment of recent-onset atrial fibrillation has been widely debated in the previous research[7, 2629]. Also, the negative influence of IVS on the conversion into a sinus rhythm has been already indirectly mentioned in the literature. Furthermore, recent studies reported that the incidence of postoperative AF was higher in patients with aortic valve replacement[2]. This is generally consistent with our results as patients with hypertrophied myocardium and therefore hypertrophied IVS usually have severe aortic stenosis which was treated with surgical aortic valve replacement in our study. Therefore, taking into consideration results of previous research and our study and despite the small patient cohort in the present observation, thickness of the IVS might play a significant role in affecting the success of pharmacological conversion rate.

Analyzing data on pharmacological conversion rate in postcardiotomy patients and patients who had not undergone cardiac surgery, we found out that application of both vernakalant and flecainide as monotherapy was associated with worse conversion rates in postcardiotomy patients. Kowey et al. in his prospective randomized double-blind trial reported on the success rate of conversion with vernakalant into a sinus rhythm in postcardiotomy patients which was 47% compared to the success rate in non-surgical patients of up to 55%[7, 26]. While there were no useful data regarding conversion rate of postcardiotomy patients after flecainide treatment, the success rate to this drug in non-cardiac surgery patients ranged between 50–67.5% in the previous literature[3033]. Not surprisingly, our findings showed a conversion rate after vernakalant monotherapy which was slightly higher however comparable to the study by Kowey et al. and resulted in 52.2% of success. Furthermore, our study showed a significant improvement in the conversion rate into a stable sinus rhythm to 60.9% after additional application of flecainide in patients who did not convert after monotherapy with vernakalant. In interpreting these findings, we assume that the combination of both antiarrhythmic drugs is more effective in converting recent onset atrial fibrillation in carefully selected groups of patients with AF after cardiac surgery. This might be also important in regards to the fact that a substantial number of patients resist EC due to sedation and further fears related to this more demanding procedure. Despite that, our analysis revealed a 91.3% conversion rate into a stable sinus rhythm after treatment with both antiarrhythmics and EC. Taking into consideration the fact that two patients who were not converted in a sinus rhythm after vernakalant and flecainide administration, refused further electric cardioversion attempt, the combined cardioversion rate might have been even higher.

Several authors suggested that the use of flecainide in patients with structural heart defects may contribute to a pro-arrhythmogenic side effects[34, 35]. These studies are particularly focused on the risk of ventricular arrhythmia in patients with previous coronary heart disease and myocardial infarction or ischemic cardiomyopathy. Therefore, we excluded patients with ischemic cardiomyopathy and previous myocardial infarction from our observation, as mentioned before. Furthermore, vernakalant with the most common side-effects being dysgeusia, sneezing, paresthesia, nausea, and hypotension appeared to have no side-effects even in combination with flecainide in our study. Also, there were no drug-induced life-threatening ventricular arrhythmias observed after combinational treatment with vernakalant/flecainide. However, it might be related to the relatively low number of patients observed in our investigation.

“Classic” antiarrhythmic drugs, such as amiodaron or Beta-blockers were also shown to be an effective treatment in post cardiotomy patients[36]. Compared to a high conversion rate and quick action of vernakalant shown in our study and previous research, amiodaron treatment for recent-onset AF only resulted in 5% conversion within the first 90 min with similar results in post cardiotomy patients[37]. However, well-designed trials evaluating amiodarone and focused on postoperative medical cardioversion are lacking. Also, treatment with this drug can lead to serious complications such as non-cardiac toxicity including pulmonary, hepatic, thyroid, and neurologic side-effects. Moreover, its intravenous administration can be associated with hypotension, bradycardia, and thrombophlebitis, and this agent should be used with caution in patients with severe pulmonary disease and low pulmonary resistance. In contrast, vernakalant is the first marketed drug with relative atrial selectivity and low rate of adverse events reported, indicating a higher safety profile. Beta-blockers are also relatively safe in terms of adverse events, however they are mainly used as the main agents for ventricular rate control rather than for rhythm control[36].

The result of our study may be interpreted to indicate that the oral application of 300 mg flecainide added to intravenously administered vernakalant in patients who did not convert into a sinus rhythm may not only increase the cardioversion rate but also prevent pro-arrhytmogenity and reduce side effects of vernakalant. Recent studies showed that the oral application of a single flecainide dose of 300 mg in patients with structural heart disease is safe and effective in carefully selected patients[2, 38].

Our study has several limitations. The main limitation is its non-randomized design and analysis of limited number of patients from a single institution. Furthermore, previous usual therapy strategies with non-class III antiarrhythmics, such as Beta-blockers, as well as electrolytes were not quantified. Larger prospective randomized studies with this aggressive therapy protocol are needed to confirm our preliminary results.

Conclusion

Our results show that the sequential combinational treatment with vernakalant, flecainide and EC is a recommendable and effective therapy strategy to convert rapidly new onset AF in carefully selected patients after cardiac surgery.

Author’s information

Mohamed Zeriouh, Anton Sabashnikov and Yeong-Hoon Choi share the first/senior author designation.

Notes

Abbreviations

AERP: 

Atrial effective refractory period

AF: 

Atrial fibrillation

AP: 

Action potential

CABG: 

Coronary artery bypass grafting

EC: 

Electric cardioversion

IVS: 

Interventricular septum

SR: 

Sinus rhythm.

Declarations

Acknowledgement

There are no sources of funding. The authors have no affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Authors’ Affiliations

(1)
Department of Cardiothoracic Surgery, Heart Center of the University of Cologne
(2)
Department of Cardiology, Pneumology and Angiology, Heart Center of the University of Cologne
(3)
Center for Molecular Medicine Cologne, University of Cologne
(4)
Department of Thoracic and Cardiovascular Surgery, University Hospital of Goettingen

References

  1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010, 31: 2369-2429.View ArticlePubMedGoogle Scholar
  2. Helgadottir S, Sigurdsson MI, Ingvarsdottir IL, Arnar DO, Gudbjartsson T: Atrial fibrillation following cardiac surgery: risk analysis and long-term survival. J Cardiothorac Surg. 2012, 7: 87-10.1186/1749-8090-7-87.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ommen SR, Odell JA, Stanton MS: Atrial arrhythmias after cardiothoracic surgery. N Engl J Med. 1997, 336: 1429-1434. 10.1056/NEJM199705153362006.View ArticlePubMedGoogle Scholar
  4. Blaauw Y, Crijns HJ: Treatment of atrial fibrillation. Heart. 2008, 94: 1342-1349.View ArticlePubMedGoogle Scholar
  5. Shenasa M, Soleimanieh M, Shenasa F: Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation. Europace. 2012, 14 (Suppl 5): v121-v124. 10.1093/europace/eus280.View ArticlePubMedGoogle Scholar
  6. Dunning J, Treasure T, Versteegh M, Nashef SA: Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg. 2006, 30: 852-872. 10.1016/j.ejcts.2006.09.003.View ArticlePubMedGoogle Scholar
  7. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M: Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2012, 26: 167-179. 10.1007/s10557-012-6374-4.View ArticlePubMedGoogle Scholar
  8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995, 92: 1954-1968. 10.1161/01.CIR.92.7.1954.View ArticlePubMedGoogle Scholar
  9. Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P, De Haro JC, Frank R, Villacastin JP, Vijgen J, Crijns H: Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace. 2008, 10: 21-27.View ArticlePubMedGoogle Scholar
  10. Lip GY, Tse HF: Management of atrial fibrillation. Lancet. 2007, 370: 604-618. 10.1016/S0140-6736(07)61300-2.View ArticlePubMedGoogle Scholar
  11. Schilling RJ: Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart. 2010, 96: 333-338. 10.1136/hrt.2008.155812.View ArticlePubMedGoogle Scholar
  12. Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D‘Aloia A, Curnis A:A new antiarrythmic drug in the treatment of recent onset atrial fibrillation: vernakalant. Cardiovasc Ther. 2013, 31 (5): e55-e62. 10.1111/1755-5922.12026.View ArticlePubMedGoogle Scholar
  13. Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P: Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother. 2013, 14: 347-357. 10.1517/14656566.2013.759212.View ArticlePubMedGoogle Scholar
  14. Rajagopalan B, Curtis AB: Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation. Postgrad Med. 2012, 124: 26-35. 10.3810/pgm.2012.11.2610.View ArticlePubMedGoogle Scholar
  15. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S: Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012, 33: 2719-2747.View ArticlePubMedGoogle Scholar
  16. Horwich P, Buth KJ, Legare JF: New onset postoperative atrial fibrillation is associated with a long-term risk for stroke and death following cardiac surgery. J Card Surg. 2013, 28: 8-13. 10.1111/jocs.12033.View ArticlePubMedGoogle Scholar
  17. Mediratta N, Chalmers J, Pullan M, McShane J, Shaw M, Poullis M: In-hospital mortality and long-term survival after coronary artery bypass surgery in young patients. Eur J Cardiothorac Surg. 2013, 43 (5): 1014-1021. 10.1093/ejcts/ezs459.View ArticlePubMedGoogle Scholar
  18. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL: Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993, 56: 539-549. 10.1016/0003-4975(93)90894-N.View ArticlePubMedGoogle Scholar
  19. Eltheni R, Giakoumidakis K, Brokalaki H, Galanis P, Nenekidis I, Fildissis G: Predictors of Prolonged Stay in the Intensive Care Unit following Cardiac Surgery. ISRN Nurs. 2012, 2012: 691561-PubMedPubMed CentralGoogle Scholar
  20. Borzak S, Tisdale JE, Amin NB, Goldberg AD, Frank D, Padhi ID, Higgins RS: Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay?. Chest. 1998, 113: 1489-1491. 10.1378/chest.113.6.1489.View ArticlePubMedGoogle Scholar
  21. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D: All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control study. Eur Heart J. 2013, 34 (14): 1061-1067. 10.1093/eurheartj/ehs469.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE: Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol. 2012, 109: 219-225. 10.1016/j.amjcard.2011.08.033.View ArticlePubMedGoogle Scholar
  23. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011, 57: e101-e198.View ArticlePubMedGoogle Scholar
  24. Ehrlich JR, Nattel S: Novel approaches for pharmacological management of atrial fibrillation. Drugs. 2009, 69: 757-774. 10.2165/00003495-200969070-00001.View ArticlePubMedGoogle Scholar
  25. Blomstrom-Lundqvist C, Blomstrom P: Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opin Drug Saf. 2012, 11: 671-679. 10.1517/14740338.2012.679262.View ArticlePubMedGoogle Scholar
  26. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E: Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009, 2: 652-659. 10.1161/CIRCEP.109.870204.View ArticlePubMedGoogle Scholar
  27. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004, 44: 2355-2361. 10.1016/j.jacc.2004.09.021.View ArticlePubMedGoogle Scholar
  28. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ: Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circ. 2008, 117: 1518-1525. 10.1161/CIRCULATIONAHA.107.723866.View ArticleGoogle Scholar
  29. Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH: Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010, 106: 1277-1283. 10.1016/j.amjcard.2010.06.054.View ArticlePubMedGoogle Scholar
  30. Kondili A, Kastrati A, Popa Y: Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. Wien Klin Wochenschr. 1990, 102: 510-513.PubMedGoogle Scholar
  31. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY: Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995, 75: 693-697. 10.1016/S0002-9149(99)80655-9.View ArticlePubMedGoogle Scholar
  32. Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, Niemeth C, Aicher F, Grander W, Heinze G, Kuhn P, Siostrzonek P: Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J. 2004, 25: 1318-1324. 10.1016/j.ehj.2004.04.030.View ArticlePubMedGoogle Scholar
  33. Alp NJ, Bell JA, Shahi M: Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 2000, 84: 37-40. 10.1136/heart.84.1.37.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 321 (1989): 406-412.Google Scholar
  35. Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE: Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circ. 1994, 90: 2843-2852. 10.1161/01.CIR.90.6.2843.View ArticleGoogle Scholar
  36. Khanderia U, Wagner D, Walker PC, Woodcock B, Prager R: Amiodarone for atrial fibrillation following cardiac surgery: development of clinical practice guidelines at a university hospital. Clin Cardiol. 2008, 31: 6-10. 10.1002/clc.20040.View ArticlePubMedGoogle Scholar
  37. Philip I, Berroeta C, Leblanc I: Perioperative challenges of atrial fibrillation. Curr Opin Anaesthesiol. 2014, [Epub ahead of print]Google Scholar
  38. Er F, Aslan O, Caglayan E, Gassanov N, Nia AM, Erdmann E, Rosenkranz S: Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. Clin Res Cardiol. 2010, 99: 369-373. 10.1007/s00392-010-0129-7.View ArticlePubMedGoogle Scholar

Copyright

© Zeriouh et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement